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1. Historical aspect
The first description of homocysteine (Hcy), a non-proteinogenic amino acid, was introduced 
within a case study in 1932. The first patient was an 8-year-old child with a mental retardation 
disorder who died of a myocardial infarction. Meanwhile, research continued; in 1969, Dr. 
Kilmer McCully was the first to describe the vascular pathology in patients with homocystin-
uria associated with hemodynamic changes, progressive arterial stenosis, and proliferation of 
smooth muscle cells. He also noted that homocysteine may have a causal role in any metabolic 
abnormality. This idea is the basis of his theory that a moderately elevated level of homocys-
teine is an important risk factor for cardiovascular disease. His theory was sustained only in 
1976 through a clinical trial demonstrating an increase in coronary artery disease in people 
with hyperhomocysteinemia. Since then, a particular interest has been given to studying this 
relationship.
2. Homocysteine metabolism
Homocysteine metabolism is at the crossroads of several pathways and is itself a product of the 
de novo pathway of the methionine metabolic reactions catalyzed by S-adenosylmethionine 
(SAM) and S-adenosylhomocysteine (SAH).
Homocysteine can be remethylated to methionine via the cobalamin-dependent and cobalamin-
independent pathways or can be metabolized to cysteine and other metabolites via transsulfuration 
pathway [1]. The following enzymes are involved in the homocysteine metabolism: methionine 
synthase (MS), methylenetetrahydrofolate reductase (MTHFR), cystathionine β-synthase (CBS), 
methionine synthase reductase (MTRR), and betaine-homocysteine S-methyltransferase (BHMT).
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In remethylation, homocysteine (Hcy) can be converted back to methionine in the remethyl-
ation pathway via 5-methylenetetrahydrofolate reductase (MTHFR) and methionine synthase 
(MS). In the transsulfuration pathway, Hcy is condensed with serine to form cystathionine via 
vitamin B6-dependent cystathionine β-synthase (CBS).
For proper function MS requires methylcobalamin (vitamin B12) and methionine synthase 
reductase (MTRR) [2]. Without MTRR, MS does not convert homocysteine into methionine.
MTHFR regulates the partitioning of folate-activated one-carbon units between the folate-
dependent de novo thymidylate and homocysteine remethylation pathways. MTHFR con-
verts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF) required 
for the reaction of remethylation of homocysteine and away from thymidine synthesis. 
5-Methyltetrahydrofolate acts as a substrate with vitamin B12 and S-adenosylmethionine serv-
ing as cofactors for methionine synthase. The functionality of methionine synthase is main-
tained by methionine synthase reductase, which catalyzes the reductive reactivation of inactive 
MS bound to oxidized cobalamin to maintain its active form using S-adenosylmethionine 
(SAM). Polymorphisms in MS and MTHFR were suggested to act independently to elevate 
Hcy concentrations by compromising different parts of the pathway that might not interact 
directly with one another [3].
The genetic variations of MTHFR have been reported to be associated with the gene defi-
ciency and associated with susceptibility to occlusive vascular disease, neural tube defects, 
Alzheimer’s disease, and other forms of dementia [4, 5]. In a study, C677T polymorphism in 
MTHFR was shown to associate with higher plasma homocysteine and the risk of brain atro-
phy and brain volume deficit [6]. The mutation of MTHFR results in reduced enzymatic activ-
ity and consequently accumulation of homocysteine. Plasma concentrations of folate, B12, and 
5-MTHF were reduced in elderly (over 65 years old) patients with dementia [7]. There was 
no difference found in DNA methylation between demented patients and age-corresponding 
controls. However, changes in DNA methylation correlated with the folate status. Two single 
nucleotide polymorphisms (C677T and A1298C) in the methylenetetrahydrofolate (MTHFR) 
gene are important genetic predictors of Hcy level [8].
It was reported that deficit of B12, B6, and folate can lead to cognitive deficit. High level of 
homocysteine was observed in B12 deficiency even when the level of folate was sufficient. 
Only concurrent supplementation of B vitamins and folic acid has been efficient in diminish-
ing the level of Hcy [9].
Methionine is first converted to S-adenosylmethionine, which can lose its methyl group to 
form S-adenosylhomocysteine (adoHcy). This demethylated product is hydrolyzed to free 
homocysteine which undergoes a reaction with serine, catalyzed by cystathionine β-synthase, 
to yield cystathionine. CBS catalyzes the pyridoxal phosphate-dependent conversion of homo-
cysteine to cystathionine. In the animal model, it was shown that during aging the expression 
of CBS was not changed, whereas activity significantly decreased [10]. Subsequently, the 
decline in CBS activity due to nitration was attributed to observed elevated level of Hcy. High 
Hcy levels results from diet with an excess of methionine. In mice models it was shown that 
high methionine diet brings up the level of homocysteine in Cbs (+/+) and Cbs (+/−) [11].
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3. Hyperhomocysteinemia and diseases
The following forms of homocysteine can be found in the plasma:
1. Free Hcy
2. Protein-bound Hcy (S-linked and N-linked)
3. Oxidized forms of Hcy
4. Hcy-thiolactone [1]
Hyperhomocysteinemia (HHcy) may arise from genetic defects of enzymes involved in 
homocysteine metabolism. There are numerous factors that influence Hcy level like age, 
gender, cigarette smoking, coffee and alcohol intake, and polymorphisms in genes encoding 
enzymes acting in one-carbon metabolism.
Hyperhomocysteinemia is defined when plasma level is more than 15 μmol/L [1]. Total con-
centration of homocysteine in plasma of healthy humans is low, and its level is between 5.0 
and 15.0 μmol/L. Several types of HHcy are classified in relation to the total Hcy concentra-
tion: moderate (16–30 μM), intermediate (31–100 μM), and severe (higher than 100 μM) [12].
Hcy level associates with all-cause mortality risk in a linear fashion, and the risk of mortal-
ity increases for each 5 μmol/L Hcy by 33.6% [13]. In patients with heart failure, the level 
of Hcy reached 17.8 ± 0.7 μmol/L; Hcy reached the highest level of 20.2 ± 1.5 μmol/L in 
patients with cognitive impairment. Hcy exerts multiple neurotoxic mechanisms that are 
relevant in the development of neurodegenerative diseases such as Alzheimer’s disease [14]. 
Hcy at the concentration over 30 μM associates with cognitive dysfunction [15]. The preva-
lence of hyperhomocysteinemia was significant in patients with hypertension and ischemic 
heart disease. Chronic hyperhomocysteinemia causes vascular remodeling by instigating 
vein phenotype in the artery, thus leading to cerebrovascular and vascular dysfunctions. 
Interestingly, a large proportion of vegetarians develop hyperhomocysteinemia and serum 
vitamin B12 deficiency [16]. Positive association was reported between Hcy level and physi-
cal inactivity.
A high Hcy level associates with an increased reactive oxygen species (ROS) production in 
the elderly [17–19]. Hcy exerts neurotoxicity by suppressing activities of Na+/K+ ATPase, 
superoxide dismutase (SOD), and glutathione peroxidase (GPx) and diminishing glutathi-
one content. Redox balance disruptions and excessively generated ROS promote neuronal 
death in the cerebral cortex. Homocysteine (Hcy) toxicity is mediated by the posttranslational 
modification of proteins by its metabolite, homocysteine thiolactone (HTL). It was shown 
that HTL-modified cytochrome c causes conversion of the hexa-coordinate cytochrome c to 
a penta-coordinate species and conformational alterations affecting the packing of the apolar 
groups. Such changes lead to the reduction of the heme moiety and activation of peroxidase-
like function of cytochrome c [20].
Clinically the measurement of homocysteine is considered important to diagnose homocys-
tinuria to identify individuals with the risk of developing cobalamin or folate deficiency states 
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and to assess the risk factor for young cardiovascular disease (CVD) patients (<4 years). In 
known cases of CVD, high homocysteine levels should be used as a prognostic marker for 
CVD events and mortality. Increased homocysteine levels with low vitamin concentrations 
should be handled as potential vitamin deficiency state. Supplementation of diets with folic 
acid, cobalamin, and pyridoxine appears to provide protection by lowering homocysteine 
levels in the blood.
The homocysteine level increases with an increasing age and is generally higher in males as 
compared to females. Homocysteine has been suggested to be a risk factor for fracture, but the 
causal relationship is not yet clear [21]. Homocysteine levels can be taken as an early indica-
tor for the detection of cardiovascular diseases as the Hcy level increases after a myocardial 
infarction or stroke. No clear cut data is available that rules out homocysteine as a marker for 
heart disease.
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